The 5-HT Receptor Biased Agonists, NLX-204 and NLX-101, Display Ketamine-like RAAD and Anti-TRD Activities in Rat CMS Models
Overview
Affiliations
Objectives: NLX-101 and NLX-204 are highly selective serotonin 5-HT 'biased' agonists, displaying potent and efficacious antidepressant-like activity upon acute administration in models such as the forced swim test.
Methods: we compared the effects of repeated administration of NLX-101, NLX-204 and ketamine in the chronic mild stress (CMS) model of depression, considered to have high translational potential, on sucrose consumption (anhedonia measure), novel object recognition (NOR; working memory measure) and elevated plus maze (EPM; anxiety measure) in male Wistar and Wistar-Kyoto rats (the latter being resistant to classical antidepressants).
Results: in Wistar rats, NLX-204 and NLX-101 (0.08-0.16 mg/kg i.p.), like ketamine (10 mg/kg i.p.) dose-dependently reversed CMS-induced sucrose intake deficit from treatment Day 1, with nearly full reversal observed at the higher dose at Days 8 and 15. These effects persisted for 3 weeks following treatment cessation. In the NOR test, both doses of NLX-101/NLX-204, and ketamine, rescued the deficit in discrimination index caused by CMS on Days 3 and 17; all three compounds increased time spent in open arms (EPM) but only NLX-204 achieved statistical significance on Days 2 and 16. In Wistar-Kyoto rats, all 3 compounds were also active in the sucrose test and, to a lesser extent, in the NOR and EPM. In non-stressed rats (both strains), the three compounds produced no significant effects in all tests.
Conclusions: these observations further strengthen the hypothesis that biased agonism at 5-HT receptors constitutes a promising strategy to achieve rapid-acting/sustained antidepressant effects combined with activity against TRD, in addition to providing beneficial effects against memory deficit and anxiety in depressed patients.
Trends in research on novel antidepressant treatments.
Zelek-Molik A, Litwa E Front Pharmacol. 2025; 16:1544795.
PMID: 39931695 PMC: 11807967. DOI: 10.3389/fphar.2025.1544795.
Yoshii T, Oishi N, Sotozono Y, Watanabe A, Sakai Y, Yamada S Sci Rep. 2024; 14(1):3601.
PMID: 38351316 PMC: 10864298. DOI: 10.1038/s41598-024-53103-2.
Preclinical models of treatment-resistant depression: challenges and perspectives.
Kolasa M, Faron-Gorecka A Pharmacol Rep. 2023; 75(6):1326-1340.
PMID: 37882914 PMC: 10661811. DOI: 10.1007/s43440-023-00542-9.